Join the Hepatocellular Carcinoma group to help and get support from people like you.
Hepatocellular Carcinoma News
Related terms: Malignant Hepatoma, HCC, Liver Cancer
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
TUESDAY, Sept. 17, 2024 – A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study...
Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
TUESDAY, Sept. 10, 2024 – For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone,...
Women With Liver Cancer Less Likely Than Men to Receive Liver Transplant
MONDAY, Sept. 9, 2024 – Women with hepatocellular carcinoma (HCC) are less likely to receive a deceased-donor liver transplant (DDLT) and more likely to die while wait-listed than men, according to a...
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
THURSDAY, Aug. 22, 2024 – Patients treated with neoadjuvant immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) have higher-risk disease features but achieve outcomes...
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
FRIDAY, Aug. 16, 2024 – For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does not worsen outcomes, according to research...
Cholesterol Absorption Inhibitors May Cut Risk for Liver Cancer
WEDNESDAY, July 31, 2024 – The use of cholesterol absorption inhibitors is associated with a reduced risk for liver cancer, according to a study published online July 29 in Cancer. Shahriar A. ...
Can Non-Statin Cholesterol Meds Help Your Liver?
WEDNESDAY, July 31, 2024 – Prior studies have found that statin meds can help lower liver cancer risks, and new research suggests that at least one non-statin cholesterol drug can do the same. A...
New Tool Could Spot Liver Cancer Early, Upping Survival
WEDNESDAY, June 19, 2024 – A new AI-driven blood test could improve detection of liver cancer, which is one of the most fatal cancers because early diagnosis is difficult. The test looks for “fusion ...
Combo Therapy May Be Advance Against Liver Cancer
MONDAY, May 6, 2024 – A new combination therapy appears to boost the response rate for liver cancer patients receiving immunotherapy, according to results from a phase 2 clinical trial. The combo...
Adding Vaccine to Immunotherapy for Liver Cancer Shows Promise in Early Trial
TUESDAY, April 9, 2024 – A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study...
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 – For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization...
Mexican Americans Face Higher Odds for Liver Cancer With Each New Generation
WEDNESDAY, Nov. 22, 2023 – The risk of developing liver cancer appears to be rising with each successive generation of Mexican-Americans, especially men, a new report finds. “Liver cancer is b...
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 – Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to a study presented at...
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
MONDAY, Nov. 20, 2023 – For Mexican Americans, increasing generational status is associated with an increased risk for hepatocellular carcinoma (HCC), according to a study published online Nov. 20...
FDA Approves Imjudo (tremelimumab) in Combination with Imfinzi for Patients with Unresectable Hepatocellular Carcinoma
24 October 2022 – AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular c...